Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
about
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically activeP-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociceptionCholinergic modulation by opioid receptor ligands: potential application to Alzheimer's diseaseFunctional impact of ABCB1 variants on interactions between P-glycoprotein and methadoneHow Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.A proposed role for efflux transporters in the pathogenesis of hydrocephalusDifferential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsTargeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.The Impact of Opioids on Cardiac Electrophysiology.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Pharmacogenomics of methadone maintenance treatment.A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine.Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain.New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors.The effect of P-glycoprotein on methadone hydrochloride flux in equine intestinal mucosa.An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level.Variation in the α2A-adrenergic receptor gene and risk of gestational diabetes.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT).
P2860
Q24629014-840622C2-3E7F-4854-9791-935366863EA8Q24631289-B0DAB23B-2875-4E41-9798-0FE1A0B852B0Q26999066-84091C2C-01C2-42A1-BB19-A3BDB318BD08Q28488223-26749EEF-4887-4655-827D-6500B7459821Q31043972-7882737F-5029-4FE0-90CD-190D5A805027Q33456441-65F46E54-0B19-45D2-AA0C-5CFC0DCDDD3FQ33574623-E630EB3A-625B-49A3-9709-1270CDEB3D71Q34147836-42647102-E2E2-43D0-A63E-9F2C9948A51DQ34359979-F146B943-B66D-49D0-A17F-70318610758AQ35738885-403F204B-C366-4C4C-BF85-2EBD5F0779A5Q35855634-BBC278D5-87B7-49D6-B534-3E6635971FF3Q36036200-A7902A38-F33C-41E0-A46D-EA25F4B642A8Q36441533-3ED2E9C2-A584-4219-A64A-310BB4BA29E9Q36728665-45A76DC0-CF8B-40D3-B9E4-02B35276DE51Q37579953-0E53BA8B-1957-4070-8C65-5F2616D870B7Q38093852-6134284F-DBB6-48B0-A7A3-2761586FE195Q38222510-BE5B8C8E-A569-4D6C-95F5-59CD4AD6A13EQ38661092-51DCDD8F-CB16-4AF5-A64F-1C5FA0FB6C7AQ38932100-3E6BF087-AE50-4971-B7AA-FEF0D12B50FBQ39285381-3523B37D-560E-40CE-9950-0DB11426004BQ39607835-3EDAF867-2485-4717-8F30-06278989A46AQ43943908-5418CEE2-F448-47E9-9F10-D900CD905CA1Q48185747-B5077EEE-4411-4B0F-847B-1F993E0C1057Q49617650-494D5ACE-FCAE-4044-9FA8-39A763E56AFFQ51579656-649E85B4-6C67-456B-AA3D-98F44C173216Q51710092-56175509-78BA-4FA5-AB4F-F5249416751E
P2860
Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Differential involvement of P- ...... vitro and in vivo evaluation.
@en
Differential involvement of P- ...... vitro and in vivo evaluation.
@nl
type
label
Differential involvement of P- ...... vitro and in vivo evaluation.
@en
Differential involvement of P- ...... vitro and in vivo evaluation.
@nl
prefLabel
Differential involvement of P- ...... vitro and in vivo evaluation.
@en
Differential involvement of P- ...... vitro and in vivo evaluation.
@nl
P2093
P2860
P356
P1476
Differential involvement of P- ...... vitro and in vivo evaluation.
@en
P2093
Alan L Myers
Andrew Coop
Hazem E Hassan
Natalie D Eddington
P2860
P304
P356
10.1002/JPS.21770
P407
P577
2009-12-01T00:00:00Z